Dynavax Technologies Corporation (DVAX)
Stock Price:
$7.68 USD
-1.15 (-12.98%)
Updated Aug 7, 2020 3:01 PM EDT - Market open
Key Info
| Market Cap |
707.51M |
| Revenue (ttm) |
34.73M |
| Net Income (ttm) |
-125.52M |
| Shares Out |
108.80M |
| EPS (ttm) |
-1.61 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$7.68 |
| Previous Close |
$8.82 |
| Change ($) |
-1.15 |
| Change (%) |
-12.98% |
| Day's Open |
8.15 |
| Day's Range |
7.08 - 8.23 |
| Day's Volume |
7,200,864 |
| 52-Week Range |
1.80 - 12.44 |
More Stats
| Market Cap |
707.51M |
| Enterprise Value |
794.32M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
108.80M |
| Float |
76.59M |
| EPS (basic) |
-1.71 |
| EPS (diluted) |
-1.61 |
| FCF / Share |
-1.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
15.24M |
| Short Ratio |
2.08 |
| Short % of Float |
16.67% |
| Beta |
1.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
20.37 |
| PB Ratio |
82.44 |
| Revenue |
34.73M |
| Operating Income |
-116.30M |
| Net Income |
-125.52M |
| Free Cash Flow |
-129.09M |
| Net Cash |
-86.81M |
| Net Cash / Share |
-0.94 |
| Gross Margin |
-107.35% |
| Operating Margin |
-334.85% |
| Profit Margin |
-319.10% |
| FCF Margin |
-371.67% |
| ROA |
-19.59% |
| ROE |
-390.20% |
| ROIC |
-26.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.00*
(108.47% upside)
Low
14.0
Current: $7.68
High
20.0
Target: 16.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 35.22 | 8.20 | 0.33 | 11.04 | 4.05 | 11.03 | 11.25 | 9.71 | 21.61 | 23.95 |
| Revenue Growth | 329.6% | 2407.03% | -97.04% | 172.67% | -63.29% | -1.95% | 15.82% | -55.06% | -9.75% | - |
| Gross Profit | 15.83 | -13.60 | -0.87 | 11.04 | 4.05 | 11.03 | 11.25 | 9.71 | 21.61 | 23.95 |
| Operating Income | -135 | -153 | -96.01 | -111 | -105 | -91.31 | -66.49 | -67.60 | -47.58 | -47.59 |
| Net Income | -153 | -159 | -95.15 | -112 | -107 | -90.72 | -66.72 | -69.95 | -48.60 | -57.31 |
| Shares Outstanding | 72.02 | 62.36 | 52.61 | 38.51 | 32.88 | 26.29 | 19.63 | 17.05 | 12.51 | 8.25 |
| Earnings Per Share | -2.16 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.83 | -4.10 | -3.90 | -6.90 |
| Operating Cash Flow | -121 | -131 | -77.52 | -107 | -92.56 | -73.74 | -58.67 | -43.81 | -47.12 | -51.37 |
| Capital Expenditures | -22.40 | -4.19 | -0.67 | -7.76 | -6.97 | -1.67 | -1.63 | -2.93 | -1.14 | -0.42 |
| Free Cash Flow | -144 | -135 | -78.19 | -115 | -99.53 | -75.41 | -60.30 | -46.74 | -48.26 | -51.79 |
| Cash & Equivalents | 151 | 146 | 192 | 82.02 | 197 | 123 | 190 | 126 | 115 | 72.81 |
| Total Debt | 216 | 101 | - | - | - | 9.56 | - | - | 12.81 | 10.94 |
| Net Cash / Debt | -65.18 | 45.28 | 192 | 82.02 | 197 | 114 | 190 | 126 | 102 | 61.87 |
| Assets | 279 | 211 | 219 | 110 | 217 | 138 | 205 | 140 | 134 | 84.25 |
| Liabilities | 271 | 148 | 19.24 | 20.48 | 29.55 | 37.81 | 18.33 | 24.93 | 34.22 | 32.14 |
| Book Value | 8.29 | 63.07 | 200 | 89.20 | 187 | 100 | 186 | 115 | 99.88 | 52.11 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Dynavax Technologies Corporation |
| Country |
United States |
| Employees |
231 |
| CEO |
Ryan Spencer |
Stock Information
| Ticker Symbol |
DVAX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DVAX |
| IPO Date |
February 19, 2004 |
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.